SCHEMBL177224

SCHEMBL177224

COc1cc(N)cc(C(=O)O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
RXRA P19793 1/20 0.50
KDM4E B2RXH2 2/20 0.47
CA12 O43570 1/20 0.47
CA3 P07451 1/20 0.47
PKM P14618 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47
TPMT P51580 2/20 0.45
CASR P41180 1/20 0.44
PTGS2 P35354 1/20 0.44
LMNA P02545 2/20 0.44
CNR2 P34972 1/20 0.43
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30197284 1.00 CA1 (0.50) CA1CA2RXRAKDM4ECA12
Hydrochloric Acid SCHEMBL3767130 0.98 RXRA (0.49) CA1CA2RXRAKDM4ECA12
3,5-Dimethoxybenzoic Acid SCHEMBL503889 0.85 RXRA (0.64) CA1CA2RXRAKDM4ECA12
SCHEMBL39734 0.85 CA1 (0.60) CA1CA2RXRAKDM4ECA12
SCHEMBL3087859 0.84 PARP1 (0.56) CA1CA2PARP1ALDH1A1KMT2A
Hydrochloric Acid SCHEMBL3361588 0.83 CA1 (0.58) CA1CA2RXRAKDM4ECA12
3,5-Dimethoxybenzoic Acid SCHEMBL20592058 0.83 RXRA (0.62) CA1CA2RXRAKDM4ECA12
Hydrochloric Acid SCHEMBL19118500 0.83 CA1 (0.58) CA1CA2RXRAKDM4ECA12
3,5-Dimethoxybenzoic Acid SCHEMBL5668197 0.83 RXRA (0.62) CA1CA2RXRAKDM4ECA12
SCHEMBL414382 0.82 CA1 (0.52) CA1CA2KDM4ECA12PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117800914-B Anti-SARS-CoV-2 virus armstrong mutant inhibitor 中国人民解放军海军军医大学 2026-05-19 CN claimed
WO-2025085689-A1 EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-24 WO claimed
CN-106232216-B Composite polyamide membrane post-treated with nitrous acid 陶氏环球技术有限责任公司 2019-10-11 CN claimed
US-9943810-B2 Composite polyamide membrane post-treated with nitrous acid DOW GLOBAL TECHNOLOGIES LLC (US) 2018-04-17 US claimed
US-20170203259-A1 COMPOSITE POLYAMIDE MEMBRANE POST-TREATED WITH NITROUS ACID THE DOW CHEMICAL COMPANY 2017-07-20 US claimed
CN-106232216-A Composite polyamide membrane post-treated with nitrous acid 陶氏环球技术有限责任公司 2016-12-14 CN claimed
WO-2015175258-A1 COMPOSITE POLYAMIDE MEMBRANE POST-TREATED WITH NITROUS ACID DOW GLOBAL TECHNOLOGIES LLC (US) 2015-11-19 WO claimed
CN-117800914-B Anti-SARS-CoV-2 virus armstrong mutant inhibitor 中国人民解放军海军军医大学 2026-05-19 CN disclosed
US-12391647-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2025-08-19 US disclosed
WO-2025085689-A1 EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-24 WO disclosed
CN-115335378-B Monoacylglycerol lipase modulators 詹森药业有限公司 2025-03-04 CN disclosed
CN-114796204-B Application of ansa triene compounds in antiviral infection medicines and preparation method thereof 中国人民解放军海军军医大学 2024-07-16 CN disclosed
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 US disclosed
WO-2008094438-A1 MACROLACTAMS BY ENGINEERED BIOSYNTHESIS KOSAN BIOSCIENCES INCORPORATED (US) 2008-08-07 WO disclosed
US-20070105890-A1 Novel condensed imidazole derivative DAINIPPON SUMITOMO PHARMA CO., LTD 2007-05-10 US disclosed
EP-1690863-A1 NOVEL CONDENSED IMIDAZOLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-08-16 EP disclosed
US-20040116654-A1 Heterogeneous foldamers containing alpha, beta, and/or gamma-amino acids NATIONAL SCIENCE FOUNDATION 2004-06-17 US disclosed
WO-2004018644-A2 HETEROGENEOUS FOLDAMERS CONTAINING α, β, AND/OR Ϝ-AMINO ACIDS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2004-03-04 WO disclosed
US-6165998-A Antifungal agents SCRIPTGEN PHARMACEUTICALS, INC. (US) 2000-12-26 US disclosed
WO-1999013714-A1 ANTIFUNGAL AGENTS SCRIPTGEN PHARMACEUTICALS, INC. (US) 1999-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105890-A1 Novel condensed imidazole derivative DPP4, DPP7, DPP3 CA1 2706/4885CA2 1527/4885RXRA 2749/4885
US-12391647-B2 Benzamide compound and preparation method, use, and pharmaceutical composition thereof JAK2, STAT3, STAT5A CA1 1768/4885CA2 573/4885RXRA 2841/4885
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP CA1 2588/4885CA2 3102/4885RXRA 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.